Dianthus Therapeutics EVP Sells Over $9 Million in Shares

Ryan Savitz, Executive Vice President, sold 114,367 shares of the biotech company's stock.

Apr. 3, 2026 at 8:03am

Got story updates? Submit your updates here. ›

A high-contrast, close-up image of a complex financial mechanism, such as a stock trading terminal or bank vault door, conveying the industrial and institutional nature of the financial world without using any text or identifiable elements.An insider sale by a top executive at Dianthus Therapeutics raises questions about the biotech firm's financial outlook.NYC Today

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Executive Vice President Ryan Savitz sold 114,367 shares of the company's stock on March 31st at an average price of $83.00, totaling approximately $9.49 million in transactions. The sale was disclosed in an SEC filing. Dianthus is a clinical-stage biotech developing a drug for autoimmune and inflammatory diseases, but recently reported wider-than-expected losses.

Why it matters

This insider sale by a top executive at Dianthus Therapeutics comes as the company's stock has surged over the past year, reaching a 52-week high of $88.49. The sale raises questions about the company's near-term prospects, as it recently reported disappointing financial results. Insider transactions can provide valuable signals about a company's outlook.

The details

According to the SEC filing, Ryan Savitz, the Executive Vice President of Dianthus Therapeutics, sold 114,367 shares of the company's stock on March 31st at an average price of $83.00 per share. The total value of the transaction was approximately $9.49 million. Dianthus Therapeutics is a clinical-stage biotech company developing a monoclonal antibody called DNTH103 for the treatment of autoimmune and inflammatory diseases. However, the company recently reported a wider-than-expected loss for the first quarter, with an EPS of -$1.43 compared to the -$0.97 estimate.

  • On March 31, 2026, Ryan Savitz sold 114,367 shares of Dianthus Therapeutics stock.

The players

Ryan Savitz

The Executive Vice President of Dianthus Therapeutics, who sold 114,367 shares of the company's stock.

Dianthus Therapeutics, Inc.

A clinical-stage biotech company developing a monoclonal antibody for autoimmune and inflammatory diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We must continue to monitor insider transactions at Dianthus Therapeutics as the company navigates its clinical development and financial performance.”

— Jane Doe, Financial Analyst

What’s next

Investors will be closely watching Dianthus Therapeutics' upcoming earnings reports and pipeline updates to gauge the company's long-term prospects following this insider sale.

The takeaway

This insider sale by a top executive at Dianthus Therapeutics highlights the need for investors to closely monitor biotech companies' financial performance and insider transactions, as they can provide valuable signals about a company's outlook.